Featured Research

from universities, journals, and other organizations

Extracellular Protein Sensitizes Ovarian Cancer Cells To Chemotherapy

Date:
December 12, 2007
Source:
Cell Press
Summary:
Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy. The research, published by Cell Press in the December issue of Cancer Cell, helps to explain why many patients develop resistance to the taxane class of drugs and may lead to improved treatment of ovarian cancer.

Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy. The research, published by Cell Press in the December issue of Cancer Cell, helps to explain why many patients develop resistance to the taxane class of drugs and may lead to improved treatment of ovarian cancer.

Cancer cells divide rapidly and undergo extensive microtubule-driven restructuring as they proliferate. Taxanes, such as paclitaxel (Taxol), interfere with the dynamic growth of microtubules by directly binding to them and making them more stable and, as a result, disrupt the normal process of cell division. Paclitaxel has been used extensively to treat lung, ovarian and breast cancers but drug resistance limits the clinical usefulness of this drug to only about half of breast or ovarian cancer patients.

Although it is clear that taxane resistance is associated with a loss of stable microtubules and that microtubule stability can be influenced by signals from the extracellular matrix (ECM), a role for ECM proteins in the modulation of paclitaxel sensitivity has not been established. To explore the connection between regulation of microtubules and taxane resistance, Dr. James D. Brenton from the Cancer Research UK Cambridge Research Institute in Cambridge, England and colleagues performed an extensive examination of ovarian cancer cell lines that were sensitive or resistant to paclitaxel.

The researchers found that the ECM protein, transforming growth factor beta induced (TGFBI), was significantly reduced in paclitaxel-resistant cells. Importantly, TGFBI mediated sensitization to paclitaxel and loss of TGFBI was sufficient to induce paclitaxel resistance. TGFBI induced microtubule stabilization that was dependent on integrin-mediated FAK and Rho signaling. Further, analysis of ovarian cancer samples taken after treatment with paclitaxel revealed that paclitaxel-induced cell death was associated with high levels of TGFBI expression.

These results identify TGFBI as an ECM protein that induces microtubule stability and modulates sensitivity to paclitaxel in ovarian cell lines and in patients receiving paclitaxel therapy. "Our findings have potentially significant clinical applications as TGFBI protein expression is lost in one third of primary ovarian and lung cancers and FAK is low or absent in one-third of ovarian cancer patients," explains Dr. Brenton. "It is possible that TGFBI could be used as a biomarker for selecting patients likely to respond to taxane therapy. In addition, proteins that activate TGFBI or mimic its action may be an effective strategy for modulating the response to widely used drugs like paclitaxel or docetaxel."

The researchers include Ahmed Ashour Ahmed, Cancer Research UK Cambridge Research Institute, Cambridge, UK, and Hutchison/MRC Research Centre, Cambridge, UK, and Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Carlos Caldas, Cancer Research UK Cambridge Research Institute, Cambridge, UK, and Hutchison/MRC Research Centre, Cambridge, UK; Ashraf E.K. Ibrahim, Cancer Research UK Cambridge Research Institute, Cambridge, UK; Jillian Temple, Cancer Research UK Cambridge Research Institute, Cambridge, UK, and Hutchison/MRC Research Centre, Cambridge, UK; Cherie Blenkiron, Hutchison/MRC Research Centre, Cambridge, UK; Maria Vias, Hutchison/MRC Research Centre, Cambridge, UK; Charlie E. Massie, Hutchison/MRC Research Centre, Cambridge, UK; N. Gopalakrishna Iyer, Hutchison/MRC Research Centre, Cambridge, UK; Helena M. Earl, Hutchison/MRC Research Centre, Cambridge, UK; James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, UK, and the Hutchison/MRC Research Centre, Cambridge, UK; Anthony D. Mills, Hutchison/MRC Research Centre, Cambridge, UK; Adam McGeoch, Hutchison/MRC Research Centre, Cambridge, UK; Stephen D. Bell, Hutchison/MRC Research Centre, Cambridge, UK; Ronald A. Laskey, Hutchison/MRC Research Centre, Cambridge, UK; Robin Crawford, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Barbara Nicke, Cancer Research UK London Research Institute, London, UK; Julian Downward, Cancer Research UK London Research Institute, London, UK; and Charles Swanton, Cancer Research UK London Research Institute, London, UK.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Extracellular Protein Sensitizes Ovarian Cancer Cells To Chemotherapy." ScienceDaily. ScienceDaily, 12 December 2007. <www.sciencedaily.com/releases/2007/12/071210163425.htm>.
Cell Press. (2007, December 12). Extracellular Protein Sensitizes Ovarian Cancer Cells To Chemotherapy. ScienceDaily. Retrieved April 21, 2014 from www.sciencedaily.com/releases/2007/12/071210163425.htm
Cell Press. "Extracellular Protein Sensitizes Ovarian Cancer Cells To Chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210163425.htm (accessed April 21, 2014).

Share This



More Health & Medicine News

Monday, April 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins